MediLink Therapeutics (Suzhou) Co Ltd, a China-based clinical-stage biotech company, announced on Monday that it has entered into a global clinical trial collaboration and supply agreement with US biopharmaceutical company Amgen Inc (NASDAQ:AMGN).
Under the agreement, Amgen will lead a global clinical study to assess the therapeutic potential of the combination of MediLink's B7-H3-targeting antibody-drug conjugate (ADC) YL201 and Amgen's DLL3- and CD3-targeting bispecific T-cell engager (BiTE) IMDELLTRA in extensive-stage small cell lung cancer (ES-SCLC). MediLink will provide the investigational drug YL201 for the combination study.
The open-label, multi-centre Phase Ib trial is aimed at assessing the safety, tolerability, pharmacokinetics and efficacy of this combination regimen in ES-SCLC patients.
Both YL201 and IMDELLTRA have shown potential in ES-SCLC.
GE HealthCare expands AI-enabled enterprise imaging with Blackford integration
PureTech Health highlights progress in IPF research and LYT-100 at CHEST 2024
MediLink enters clinical trial collaboration and supply agreement with Amgen
Innovent Biologics partners with Jiangsu Aosaikang Pharmaceutical for lung cancer treatment
Genprex research collaborators to present positive data on Reqorsa Gene Therapy at SITC 2024
hVIVO reports positive results from RSV antiviral human challenge trial
BerGenBio reveals preliminary safety data from Phase 1b BGBC016 study in first-line NSCLC patients
Liquidia and Pharmosa expand collaboration for inhaled treprostinil
Alvotech launches confirmatory study for Entyvio biosimilar
Merck's KEYTRUDA receives new approvals in Japan for lung and urothelial cancers
Innate Pharma receives FDA clearance of IND for IPH4502, a Nectin-4 targeting ADC for solid tumours
Intas Pharmaceuticals reports positive opinion for HETRONIFLY in Europe
Insilico Medicine reveals positive preliminary results from ISM001-055Phase IIa clinical trial